All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.
The purpose of this first-in-human (FIH) study of BLZ945 given as a single agent or in combination with PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLZ945, administered orally, as a single agent or in combination with PDR001, administered intravenously (i.v.) in adult patients with advanced solid tumors.
Dose escalation will be guided by a Bayesian logistic regression model with overdose control. Once MTD/ RP2D is declared, glioblastoma patients will be enrolled in the phase II part to further assess the preliminary anti-tumor activity of BLZ945 as single agent and in combination with PDR001.
Advanced Solid Tumors
Oct 21, 2016
Mar 17, 2022
18 Years and older (Adult, Older Adult)
Phase I: Patients with advanced/metastatic solid tumors, with measurable or unmeasurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Phase I: Patients with a site of disease amenable to biopsy, and willing to undergo a new tumor biopsy at screening, and during treatment.
Phase II: Patients with advanced/metastatic/recurrent isocitrate dehydrogenase (IDH) wild-type glioblastoma, with at least one measurable lesion as determined by RANO
Other protocol defined inclusion criteria may apply
History of severe hypersensitivity reactions to monoclonal antibodies.
Impaired cardiac function or clinically significant cardiac disease.
Active autoimmune disease or a documented history of autoimmune disease.
Systemic steroid therapy or any immunosuppressive therapy
Use of any vaccines against infectious diseases within 4 weeks of initiation of study treatment.
Patient receiving treatment with medications that either strong inducers or inhibitors of CYP2C8 or CYP3A4/5, or patients receiving medication that prohibits proton pump inhibitors and that cannot be discontinued at least 1 week prior to start of treatment and for the duration of the study.
Other protocol defined exclusion criteria may apply.
Dana Farber Cancer Institute Dana Farber Cancer Institute
Sarah Cannon Research Institute Sarah Cannon Research
UT M.D Anderson Cancer Center
Cancer Therapy and Research Center UT Health Science Center